Citigroup raises target for Merck & Co. stock to USD 145.00

Published on 10/14/2026 at 14:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 29, 2026. Merck & Co. stock costs EUR 127.25 on October 14, 2026, minus 0.55 percent versus the Xetra close.

Analyst target and reporting date

Citigroup lifted its target from USD 125.00 to USD 145.00 on October 12, 2026.
Merck is scheduled to report third-quarter 2026 results on October 29, 2026.
Merck & Co. stock costs EUR 127.25 at Lang & Schwarz on October 14, 2026 at 2:30 p.m. CEST, minus 0.55 percent versus the Xetra close of October 13, 2026, 5.38 percent below the 52-week high.
Merck & Co. had a P/E ratio of 113.58 and a USD 350.7 billion market capitalization on October 13, 2026.

Schwarzweiß-Dokumentarfoto einer pharmazeutischen Produktionslinie mit Arbeitern — Schwarzweiß-Reportage aus Produktionsanlage illustriert Pharmasektor von Merck & Co. Inc., ISIN US58933Y1055, dokumentarisch fotografiert, Illustration mit AI erstellt.

Citigroup raised its Merck & Co. price target from USD 125.00 to USD 145.00 on October 12, 2026, while keeping a Neutral rating, according to Yahoo Finance. The new target lies 2.13 percent above Merck's USD 141.98 price on October 13, 2026. At Lang & Schwarz, the stock was trading at EUR 127.25 on October 14, 2026 at 2:30 p.m. CEST, minus 0.55 percent versus the Xetra close of October 13, 2026 at EUR 127.96.

Third-quarter results due October 29

Merck's next reported milestone is its third-quarter 2026 results, scheduled for October 29, 2026, according to Yahoo Finance. The same calendar lists diluted earnings per share expectations of USD 2.12, down 17.83 percent from USD 2.58 in the year-ago quarter.

Stock stays below its yearly high

The euro quote sits within a 52-week range of EUR 71.00 to EUR 134.48 as of October 14, 2026. At EUR 127.25, Merck is 5.38 percent below that high. The Lang & Schwarz bid was EUR 127.02 and the ask was EUR 127.48 at 2:30 p.m. CEST.

Sales growth meets high valuation

Merck reported USD 16.6 billion in worldwide sales for the second quarter of 2026, compared with USD 16.3 billion in the first quarter, according to the company's investor-relations page dated October 14, 2026. That represents a 1.84 percent sequential increase on the rounded figures. The company also reported a USD 1.34 billion net loss attributable to common shareholders and diluted earnings per share of minus USD 0.54 for the second quarter of 2026.

Merck's market capitalization was USD 350.7 billion and its P/E ratio was 113.58 on October 13, 2026. The elevated ratio reflects the contrast between the company's large market value and the second-quarter loss, making the October 29 report the next quantified test for earnings expectations.

Comparison with peers

Merck & Co. (NYSE, USD): minus 0.55 percent, P/E 113.58, market capitalization USD 350.7 billion.

Pfizer (NYSE, USD): minus 0.11 percent, P/E 37.49, market capitalization USD 161.7 billion.

Bristol-Myers Squibb (NYSE, USD): minus 1.58 percent, P/E 12.48, market capitalization USD 115.8 billion.

Price and investor calendar

Merck's October 14 euro price was 5.38 percent below its 52-week high and 0.55 percent below the Xetra close of October 13, 2026. The next scheduled company event is the third-quarter report on October 29, 2026.

The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.